Refractory CIDP with chronic lymphocytic leukaemia responding to chemoimmunotherapy.

Autor:	Lewis D; Department of Medicine, Southampton University Hospitals NHS Trust, Southampton, UK., Osman C; Wessex Neurological Centre, Southampton University Hospitals NHS Trust, Southampton, UK chinar.osman@uhs.nhs.uk., Allen D; Wessex Neurological Centre, Southampton University Hospitals NHS Trust, Southampton, UK., Pinto AA; Wessex Neurological Centre, Southampton University Hospitals NHS Trust, Southampton, UK., Duncombe A; Department of Haematology, Southampton University Hospitals NHS Trust, Southampton, UK., Katifi HA; Wessex Neurological Centre, Southampton University Hospitals NHS Trust, Southampton, UK.
Jazyk:	angličtina
Zdroj:	Practical neurology [Pract Neurol] 2020 Dec 29. Date of Electronic Publication: 2020 Dec 29.
DOI:	10.1136/practneurol-2020-002672
Abstrakt:	Chronic inflammatory demyelinating polyneuropathy (CIDP) has a variable clinical course with 15% remaining refractory to treatment. We report a woman with severe refractory CIDP and coexisting chronic lymphocytic leukaemia (CLL) who improved dramatically after chemoimmunotherapy appropriate for the CLL, including rituximab. A subsequent CIDP relapse after 15 months responded again to similar treatment, and the improvement has been maintained with 3-monthly rituximab infusions as sole ongoing therapy. The case suggests that CIDP refractory to conventional treatment may have associated pathology, in this case haematological malignancy, and that treating the malignancy can effectively treat the CIDP. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu